Table II.
Treatment characteristics.
| Regimen | n | Distribution (%) | Primary CSF prophylaxis %‡ (n) | Other CSF use* %‡ (n) | Rituximab administration %‡ (n) |
|---|---|---|---|---|---|
| Total | 240 | 100 | 27·5 (66) | 28·8 (69) | 81·7 (196) |
| CHOP-21-like† | 178 | 74·2 | 19·7 (35) | 34·3 (61) | 86·5 (154) |
| CHOP-14-like | 41 | 17·1 | 75·6 (31) | 9·8 (4) | 65·9 (27) |
| ACVBP-like | 9 | 3·8 | 66·7 (6) | 33·3 (3) | 77·8 (7) |
| Other regimens | 12 | 5·0 | 66·7 (8) | 8·3 (1) | 66·7 (8) |
ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CSF, colony-stimulating factor.
*
Secondary prophylaxis or treatment.
†
Includes six patients with a cycle length of 28 d.
‡
Denominator values for percentage calculations are the regimen n-values in column 2.